"A multicenter, multinational, prospective, interventional,single-arm, Phase IV study evaluating the clinicalefficacy and safety of 26 weeks of treatment with insulin glargine 300 U/mL (Gla-300) in patients with Type 2 diabetes mellitus uncontrolled on basal insulin"

drug protocol number
LPS15396
drug sponsor
SANOFI
drug study
TOUJEO
drug trial site
Sultan bin Abdulaziz Humanitarian city (Riyadh)
drug status
Ongoing
drug phase